<DOC>
	<DOC>NCT02674581</DOC>
	<brief_summary>An oral dose in healthy and renally impaired subjects to determine the drug effect for BMS-663068.</brief_summary>
	<brief_title>A Study of the Pharmacokinetics and Safety of BMS-663068 Administered in Subjects With Normal Renal Function and With Mild, Moderate, Severe and End Stage Renal Dysfunction</brief_title>
	<detailed_description />
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<criteria>Inclusion Criteria (For renal impaired subjects): Classification by renal function based on eGFR Clinical, ECG, and laboratory findings consistent with renal dysfunction BMI of 18.0 to 38.0 kg/m2 inclusive Women of child bearing potential (WOCBP) and sexually active fertile men with partners who are WOCBP must use nonhormonal highly effective birth control Slightly different inclusion criteria are defined in the protocol for healthy subjects History of uncontrolled or unstable cardiovascular, respiratory, hepatic, gastrointestinal, endocrine, hematopoietic, psychiatric, and/or neurological disease within 6 months of screening Evidence of rapidly deteriorating renal function, defined as a screening eGFR that has decreased from a previous eGFR by â‰¥ 50% within the last 3 months Current or recent (within 3 months of study drug administration) clinically significant gastrointestinal disease or gastrointestinal surgery (including cholecystectomy) that could impact the absorption of study drug Any major surgery within 4 weeks of study drug administration. Other protocol defined exclusion criteria could apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>